Commentary: From boardroom to courtroom: maximising your return - by Hitesh Patel and Simon tottman of KPMG
This article was originally published in Scrip
Pharmaceutical companies are revising their operating models in order to reduce costs and take advantage of fresh opportunities. For example, outsourcing to lower cost jurisdictions and joint-venture developments to manage the risk of large R&D investments.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
With a candidate COVID-19 therapy in clinical development, the UK’s Synairgen has raised $101m on the UK’s AIM to support clinical studies and manufacturing plans.
Although top-line efficacy results from a small study in critically ill patients with COVID-19 suggest there are therapeutic benefits associated with Relief Therapeutics/NeuroRx’s RLF-100 (aviptadil), further data are awaited from the results of a randomized clinical trial, expected later this year.